Experimental pancreatic cancer drug nearly doubles survival in Phase 3 trial

In a global Phase 3 trial of 500 patients, daraxonrasib nearly doubled median overall survival in metastatic pancreatic cancer, to 13.2 months from 6.7 months.

The drug cut the risk of death by 60% versus second-line chemotherapy and also improved progression-free survival and response rates.

Researchers saw no new safety signals, strengthening the case for daraxonrasib as a promising targeted option after first-line treatment.

The results from the RASolute 302 trial were presented at ASCO and published in The New England Journal of Medicine.